API

Telmisartan (40mg) + Hydrochlorothiazide (12.5mg)

Drug classification

Antihypertensive; Telmisartan: angiotensin II receptor blocker, Hydrochlorothiazide: thiazide diuretic.

Dosage form

Oral tablet containing telmisartan 40mg and hydrochlorothiazide 12.5mg.

API strength per dosage

Dose

Tellzy-H Tablet is typically taken once daily in adults for hypertension. Dose adjustments may be needed in renal or hepatic impairment; use caution in severe renal dysfunction and avoid in severe hepatic impairment. Safety and efficacy in children have not been established. Always individualize therapy and consult prescribing information for detailed guidance.

Mechanism of action

Telmisartan selectively blocks angiotensin II type 1 (AT1) receptors, inhibiting vasoconstriction and aldosterone effects, reducing blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing sodium and water excretion, decreasing plasma volume, and lowering blood pressure. Combined, they provide additive antihypertensive effects.

Indications

Treatment of Hypertension (high blood pressure)

Side effects

Fatigue Dizziness Nausea Diarrhea Sinus inflammation Flu like symptoms Upper respiratory tract infection

Pregnancy category

Telmisartan–hydrochlorothiazide is contraindicated in pregnancy; exposure may cause fetal toxicity, especially in the second and third trimesters. Discontinue immediately if pregnancy is detected.

Precautions

Monitor blood pressure, renal function, electrolytes (especially potassium and sodium), signs of hypotension, dehydration, gout, hypersensitivity reactions, worsening renal or hepatic impairment, avoid in pregnancy, caution in patients with severe renal or hepatic dysfunction, monitor for dizziness, avoid concomitant use with other RAAS inhibitors.

Contraindications

Hypersensitivity to telmisartan, hydrochlorothiazide, or sulfonamide-derived drugs, anuria, pregnancy, severe hepatic impairment, cholestasis, refractory hypokalemia, hypercalcemia, severe renal impairment, concomitant aliskiren in diabetes, hereditary fructose intolerance.